Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Surf,you got to give wayne and team credit for going up against the FTC.Wayne definetly on a mission.Hoping for the best.Wayne don't back down.You have alot of cirt followers hang in there.glta
CLINICAL TRIALS EXPLAINED:
In order to offer a better understanding, or brief education of clinical trials, included are some of the most common types of clinical studies, general clinical trial components, and a glossary of frequently used clinical trial terminology.
CLINICAL STUDIES DEFINED:
1 Balanced Study -- A clinical trial in which a particular type of subject is equally represented in each study group.
2 Case Report Form (CRF) -- A record of data and other information collected on each subject during a clinical study, as determined by the specific protocol.
3 Clinical Study Report -- A comprehensive description of the trial after completion including a summary of experimental methods and materials, presentation and evaluation of results, statistical analyses, and clinical appraisal.
4 Cohort Study -- A group of subjects in a clinical trial, a study population subset, followed up at regular intervals.
5 Concurrent Study -- A study being conducted at the same time as another, usually operating under the same protocol.
6 Controlled Study -- A study in which a test article is compared with a treatment that has known effects. The control group may receive a placebo, standard treatment, or no treatment.
7 Crossover Design Study -- In this type study, each subject receives one treatment for a specified time, and then, after a wash -- out period, switches to another treatment for comparison. Also, called a crossover trial.
8 Dose-Escalation Studies -- Observations carried out in early phase trials on humans, in which subjects are given the same sequence of increasing drug doses. Also, called dose response studies.
9 Double-Blind Study -- A study design where neither the investigators nor the patients knows which medication, or biologic the subject is receiving.
10 First-In-Humans Study -- First Phase 1 study in which the test product is administered to humans.
11 Interim Clinical Study Report -- A report of intermediate results and their evaluation based upon analyses performed during a trial.
12 Longitudinal Study -- A type of study or investigation where data are collected from a number of patients over a long period of time.
13 Multi-Center Study -- A study which involves several investigators conducting trials on the same protocols at their respective sites.
14 Multiple Crossover Design -- Multiple interventions are administered independently to each subject group more than one time.
15 Open-Label Study -- A non -- blinded trial where all parties have knowledge of drug and dosage being given.
16 Outpatient Study -- A study in which patients are not admitted to a hospital setting.
17 Parallel Design Study -- A study design where subjects are randomly assigned to one of two or more treatment groups, with each group being given a specific treatment for the entire study.
18 Phase 1 Studies -- A phase 1 trial is to determine human toxicity, absorption, distribution, metabolism, elimination and pharmacologic action. The primary concern is on safety. The introduction of a new drug or biologic into a small human group at a stage where previously only in vitro or animal studies were available.
19 Phase IIA Studies -- Studies to evaluate safety and efficacy in selected populations who have the disease or condition to be treated, diagnosed, or prevented.
20 Phase IIB Studies -- Generally well controlled studies that usually represent the most rigorous demonstration of a medicines effectiveness.
21 Phase III Studies -- These are large multi -- center studies to compare the new drug versus standard therapy.
22 Phase IIIB Studies -- A study conducted prior to drug approval, but after well -- controlled trials.
23 Phase IV Studies -- Studies performed after the drug has been approved for marketing. These studies are also called postmarketing surveillance studies, and may include such information as drug interactions, comparing the product to a competitor or other factors.
24 Pilot Study -- A study in a small number of patients to determine the practicality of pursuing larger -- scale clinical development for a particular product.
25 Pivotal Study -- generally well controlled randomized, double blind studies that help regulatory authorities make a decision on a investigational product.
26 Placebo-Controlled Study -- Studies where the investigational drug is compared with an inert or inactive substance, usually in a double blind type study.
27 Randomized Controlled Study -- A comparative type study where patient allocation to treatment groups is unpredictable, and achieved by a systematic randomization.
28 Single-Blind Study -- A design study where the investigators know which medication the patient is given, but the patient does not know.
CLINICAL RESEARCH GLOSSARY AND TERMS:
Active Subjects -
Any patient or person participating in a clinical trial who is actively receiving study treatment.
Admission Criteria -
Essential criteria for selecting a target population for a clinical trial.
Adverse Drug Reaction (ADR)-A reaction which is unintended and which occurs at doses normally used for prophylaxis, diagnosis, or therapy of a disease.
Adverse Event -
An undesirable experience occurring to an individual during the course of a study or clinical trial.
Blinded Studies -
A study designed to remove unintentional biases that can affect patient data when treatments are known.
Clinical Investigation -
A study to evaluate a product, drug, or biologic, as determined by the products benefits relative to risks.
Compliance -
Refers to patient compliance to protocol, Good clinical practice requirements, regulatory requirements as outlined in the clinical study.
Data Collection -
Process of recording and retrieving information from patient sources, medical records, laboratory, and x-ray reports, pharmacy records, and treatment teams.
Food And Drug Administration (FDA) -
US government agency responsible for guidelines and regulations that define how to comply with Food, Drug, and Cosmetics Act of Congress.
Freedom Of Information (FOI) -
United States law that allows public access to certain information in government files, including information regarding clinical trials.
Good Clinical Practice(GCP) -
The body of guidelines and regulations outlining the responsibilities of sponsors, investigators, monitors, and IRB’s for clinical trials, to ensure protection of safety, rights, and welfare of patients, subjects, and to ensure integrity and quality of clinical data collected.
Inclusion Criteria -
All characteristics identified in the protocol portion of the study which a patient must have in order to be enrolled in a particular study.
Indication -
The defined disease or clinical condition which an investigational product may be given after regulatory approval.
Informed Consent -
The written signature and dated voluntary confirmation of patient or subject as to willingness to participate in a clinical trial after full disclosure of information on the trial, benefits, potential risks, and rights and responsibilities.
Investigational Site -
Location of clinic, physicians office or hospital where patients are assessed and other study related activites performed.
Monitoring -
The overseeing of a clinical trial to ensure it is performed under strict applicable regulatory requirements.
Protocol -
A study protocol or formal written document that states the objectives, study design, methods, and all conditions for which the study should be performed.
Validation or Verification of Data-the procedures carried out to ensure that the final information collected in a clinical trial matches original observations.
Curriculum Vitae: Richard Marc Goldfarb, MD, FACS
George Washington University
Washington, District of Columbia
Bachelor of Science Degree - 1976
Medical School:
University of Health Sciences / Finch University
The Chicago Medical School
Chicago, Illinois
Medical Degree - 1983
Residency:
University of Medicine and Dentistry of New Jersey
Robert Wood Johnson Medical School at Camden
Cooper Hospital/University Medical Center
Camden, New Jersey
General Surgery
June 20, 1983, through August 31, 1986
Northeastern Ohio Universities College of Medicine
Akron General Medical Center
Akron, Ohio
General Surgery
July 1, 1987, through June 30, 1989
State Licensures:
Hospital Affiliations:
St. Mary Medical Center, Langhorne, Pennsylvania
Temple Lower Bucks Hospital, Bristol, Pennsylvania
Frankford Hospital (Bucks), Langhorne, Pennsylvania
Practice Experience:
1990 to Present
Surgical Care Physicians, PC
1205 Langhorne-Newtowne Road, #307
Langhorne, Pennsylvania 19047
Corporate Experience:
Environmental Industrial Solutions Corporation
President
8710 West Hillsborough Avenue, Suite 301
Tampa, Florida 33615
813-389-1535
October 2003 – Present
Bucks County Clinical Research, Inc.
Medical Director of Research and Development
201 Woolston Drive, Suite 1F
Morrisville, Pennsylvania 19067
215-736-8520
January 2002 – Present
Ion Labs, Inc.
FDA- approved prescription and pharmaceutical grade company
Medical Director
5459 115th Avenue North
Clearwater, Florida 33760
February 2002 – Present
Preservation Sciences
Board of Directors
Stock Symbol “PSVS”
September 2001 – Present
Lafayette Miracle Solutions
Medical Director/Executive Director of Sales and Marketing
117 Zonolite Street
Lafayette, Louisiana 70508
1-888-422-5833 337-593-8732
September 2001 - Present
Nutraceutical Clinical Laboratories International, Inc.
President/Chief Operating Officer – Medical Division
3542 Morris Street North
St. Petersburg, Florida 33713
September 2001 – December 2003 (division sold)
Health Care Direct Services, Inc.
President
15424 North Nebraska Avenue
Lutz, Florida 33549
November 2001 – September 2003 (division sold)
American Medical Specialties
President & CEO, Medical Director
2440 – 30th Avenue North
St. Petersburg, Florida 33713
September 2001 – August 2002 (company sold)
Clinical Experience:
Cooper Hospital/University Medical Center
Level 1 Trauma Center
Camden, New Jersey
Hahnemann University
St. Agnes Burn Center
Philadelphia, Pennsylvania
Emergency Physician Associates
Woodbury, New Jersey
House Officer, Surgical Assistant
Emergency Room Physician:
Hamilton Hospital, Hamilton, New Jersey
West Jersey Hospital, Berlin, New Jersey
Garden State Hospital, Marlton, New Jersey
University of Miami School of Medicine
Jackson Memorial Hospital
Miami, Florida
Surgical Intensive Care Unit
Bucks County Clinical Research
FDA Facility
Morrisville, Pennsylvania
Formulator of Menoease
Preservation Sciences
St. Petersburg, Florida
Formulator of Femorex
Lafayette Miracle Solutions
Lafayette, Louisiana
Formulator of Feminine Natur-Aly; Slim Natur-Aly; Bodily Cleanse Kit including Liv Flush Natur-Aly, Kidney Flush Natur-Aly, Heart Cleanse Natur-Aly and Colonic Cleanse Natur-Aly; Children’s Natur-Aly; Juice Natur-Aly; Osteo Relief Natur-Aly; Vascular Relief Natur-Aly; Colon Regulator Natur-Aly
Multiple presentations for the World Health Organizations.
Memberships in Professional Societies:
Fellow of the American College of Surgeons
American Medical Association
Ohio State Medical Association
Summit County Medical Society
New Jersey State Medical Society
Camden County Medical Society
Pennsylvania State Medical Society
Lower Bucks County Medical Society
Phi Delta Epsilon Medical Fraternity
The American Red Cross
Certifications:
Diplomate, American Board of Surgery
Basic Cardiac Life Support
Advanced Cardiac Life Support
Advanced Trauma Life Support
Advanced Laparoscopic Surgery
Awards:
University of Medicine and Dentistry of New Jersey
Robert Wood Johnson Medical School at Camden
“Resident Teaching Award” 1984-1985
Pennsylvania State
“Cancer Liaison Physician”, August 13, 2001
Committee Memberships:
University of Health Sciences, The Chicago Medical School
Founder and Editor-in-Chief of the first yearbook
Dean Student Form - President
Academic Assembly - President
Student Council
Career Interest Program - Examiner, National Convention of the American Medical Student Association
Student Volunteer Action Council
Medical Education Community Orientation Program (MECO)
Medical Records Committee, Lower Bucks Hospital
Surgical Case Review, St. Mary Medical Center
Surgical Q/A Committee, St. Mary Medical Center
Abstracts Submitted or Publications:
Born, C.T., DeLong, W.G., Goldfarb, R. M.: “Intramedullary Femoral Rodding: Early Results with the Brooker-Wills Interlocking Nail”
Goldfarb, R.M.: “Use of Topical Antibiotics for Infected Polytetrafleuroethylene Grafts”
Goldfarb, R.M., Zeitz, D.: “A Physicians Viewpoint Dealing with Death and Dying”
Goldfarb, R.M., VanderMuelen, D., Fishman, G., “Spectral Transmission Characteristics of Clear Glass and Plastic”
Goldfarb, R.M., Brown, L.: “Dapsone in the Treatment of Cutaneous Ulcers”
Goldfarb, R.M., Ruf, W. R., Davies, B.W., Marty, J.: “Perianal Bowen’s Disease: A Case Report and Review”
Goldfarb, R.M., Kaufman, K.P., Wu, D.: “Initial Assessment of the Trauma Patient with Hemophilia”
Richard Marc Goldfarb, MD, FACS
Home Address:
1042 Camellia Blvd,
#2102 Lafayette, Louisiana 70508
Office Address:
117 Zonolite Street
Lafayette, Louisiana 70508
727-244-5367 (cell)
Date of Birth:
April 14, 1954
Place of Birth:
Philadelphia, Pennsylvania
Marital Status:
Married, one child
College:
George Washington University
Washington, District of Columbia
Bachelor of Science Degree - 1976
Medical School:
University of Health Sciences / Finch University
The Chicago Medical School
Chicago, Illinois
Medical Degree - 1983
Residency:
University of Medicine and Dentistry of New Jersey
Robert Wood Johnson Medical School at Camden
Cooper Hospital/University Medical Center
Camden, New Jersey
General Surgery
June 20, 1983, through August 31, 1986
Northeastern Ohio Universities College of Medicine
Akron General Medical Center
Akron, Ohio
General Surgery
July 1, 1987, through June 30, 1989
State Licensures:
Pennsylvania - MD-038006-E
New Jersey - 49424
Ohio - 56067
Federal DEA Number:
Pennsylvania - BG1910896
New Jersey - BG0855392
Hospital Affiliations:
St. Mary Medical Center, Langhorne, Pennsylvania
Temple Lower Bucks Hospital, Bristol, Pennsylvania
Frankford Hospital (Bucks), Langhorne, Pennsylvania
Practice Experience:
1990 to Present
Surgical Care Physicians, PC
1205 Langhorne-Newtowne Road, #307
Langhorne, Pennsylvania 19047
Corporate Experience:
Environmental Industrial Solutions Corporation
President
8710 West Hillsborough Avenue, Suite 301
Tampa, Florida 33615
813-389-1535
October 2003 – Present
Bucks County Clinical Research, Inc.
Medical Director of Research and Development
201 Woolston Drive, Suite 1F
Morrisville, Pennsylvania 19067
215-736-8520
January 2002 – Present
Ion Labs, Inc.
FDA- approved prescription and pharmaceutical grade company
Medical Director
5459 115th Avenue North
Clearwater, Florida 33760
February 2002 – Present
Preservation Sciences
Board of Directors
Stock Symbol “PSVS”
September 2001 – Present
Lafayette Miracle Solutions
Medical Director/Executive Director of Sales and Marketing
117 Zonolite Street
Lafayette, Louisiana 70508
1-888-422-5833 337-593-8732
September 2001 - Present
Nutraceutical Clinical Laboratories International, Inc.
President/Chief Operating Officer – Medical Division
3542 Morris Street North
St. Petersburg, Florida 33713
September 2001 – December 2003 (division sold)
Health Care Direct Services, Inc.
President
15424 North Nebraska Avenue
Lutz, Florida 33549
November 2001 – September 2003 (division sold)
American Medical Specialties
President & CEO, Medical Director
2440 – 30th Avenue North
St. Petersburg, Florida 33713
September 2001 – August 2002 (company sold)
Clinical Experience:
Cooper Hospital/University Medical Center
Level 1 Trauma Center
Camden, New Jersey
Hahnemann University
St. Agnes Burn Center
Philadelphia, Pennsylvania
Emergency Physician Associates
Woodbury, New Jersey
House Officer, Surgical Assistant
Emergency Room Physician:
Hamilton Hospital, Hamilton, New Jersey
West Jersey Hospital, Berlin, New Jersey
Garden State Hospital, Marlton, New Jersey
University of Miami School of Medicine
Jackson Memorial Hospital
Miami, Florida
Surgical Intensive Care Unit
Bucks County Clinical Research
FDA Facility
Morrisville, Pennsylvania
Formulator of Menoease
Preservation Sciences
St. Petersburg, Florida
Formulator of Femorex
Lafayette Miracle Solutions
Lafayette, Louisiana
Formulator of Feminine Natur-Aly; Slim Natur-Aly; Bodily Cleanse Kit including Liv Flush Natur-Aly, Kidney Flush Natur-Aly, Heart Cleanse Natur-Aly and Colonic Cleanse Natur-Aly; Children’s Natur-Aly; Juice Natur-Aly; Osteo Relief Natur-Aly; Vascular Relief Natur-Aly; Colon Regulator Natur-Aly
Multiple presentations for the World Health Organizations.
Memberships in Professional Societies:
Fellow of the American College of Surgeons
American Medical Association
Ohio State Medical Association
Summit County Medical Society
New Jersey State Medical Society
Camden County Medical Society
Pennsylvania State Medical Society
Lower Bucks County Medical Society
Phi Delta Epsilon Medical Fraternity
The American Red Cross
Certifications:
Diplomate, American Board of Surgery
Basic Cardiac Life Support
Advanced Cardiac Life Support
Advanced Trauma Life Support
Advanced Laparoscopic Surgery
Awards:
University of Medicine and Dentistry of New Jersey
Robert Wood Johnson Medical School at Camden
“Resident Teaching Award” 1984-1985
Pennsylvania State
“Cancer Liaison Physician”, August 13, 2001
Committee Memberships:
University of Health Sciences, The Chicago Medical School
Founder and Editor-in-Chief of the first yearbook
Dean Student Form - President
Academic Assembly - President
Student Council
Career Interest Program - Examiner, National Convention of the American Medical Student Association
Student Volunteer Action Council
Medical Education Community Orientation Program (MECO)
Medical Records Committee, Lower Bucks Hospital
Surgical Case Review, St. Mary Medical Center
Surgical Q/A Committee, St. Mary Medical Center
Abstracts Submitted or Publications:
Born, C.T., DeLong, W.G., Goldfarb, R. M.: “Intramedullary Femoral Rodding: Early Results with the Brooker-Wills Interlocking Nail”
Goldfarb, R.M.: “Use of Topical Antibiotics for Infected Polytetrafleuroethylene Grafts”
Goldfarb, R.M., Zeitz, D.: “A Physicians Viewpoint Dealing with Death and Dying”
Goldfarb, R.M., VanderMuelen, D., Fishman, G., “Spectral Transmission Characteristics of Clear Glass and Plastic”
Goldfarb, R.M., Brown, L.: “Dapsone in the Treatment of Cutaneous Ulcers”
Goldfarb, R.M., Ruf, W. R., Davies, B.W., Marty, J.: “Perianal Bowen’s Disease: A Case Report and Review”
Goldfarb, R.M., Kaufman, K.P., Wu, D.: “Initial Assessment of the Trauma Patient with Hemophilia”
Please read thanks, **********from the Moderators handbook....
6 reasons a post gets deleted.....
1.) Duplicate – an accidental duplicate post by a member
2.) Personal Attack – when someone attacks a person, with name calling, or relating to the messenger and not the message.
3.) Spam – a message that is being posted promoting other sites, stock-related or not, that has no use in the discussion (for example, if your board is about Ford Motors, a link promoting amazing returns running a home-based business is worthless to the discussion).
4.) Vulgarity – cursing of any kind unacceptable on your board
5.) Violation of Privacy – posting of any personal identifiable information (email, real name, phone, address, etc)
People please lets stay on topic.glta
Going Public with Your Company
We assist businesses in “Going Public” fast. Any company can “Go Public” and have its own stock symbol. There are more than 15,000 public companies in the U.S. We can help your company go public on the NYSE, AMEX, NASDAQ, OTC Bulletin Board or Pink Sheets.
The NASD OTCBB (over the counter bulletin board) as well as the Pink Sheets have NO asset and NO revenue requirements. Most of the smaller companies go public first on either the NASD OTCBB or the Pink Sheets. They can quite easily move up later to NASDAQ.
In fact, if a company is interested in Going Public they may want to begin trading on the Pink Sheets. There are NO audits, NO periodic SEC reporting and they do not have to deal with Sarbanes Oxley. It also is very fast and relatively inexpensive. A company can initially begin trading on the Pink Sheets if they want to go public quickly and, if they choose, can trade on the OTCBB later very easily.
Experience Matters
The founder of our firm is a Securities Attorney. He founded his law firm over 30 years ago. His securities law firm works exclusively with public companies and companies preparing to go public. He counsels other lawyers that have clients wishing to go public.
Going Public
There are a variety of ways of going public. One way for a company to go public is an IPO. In an initial public offering a company is doing two things simultaneously. One it is raising capital; the other it is going through the procedure of going public. We assist companies with the second part which is becoming a public company and having its own stock symbol and public stock which people can buy from their broker or online like any other public company.
Going public in this manner is ideal for companies that may not be large enough to attract an underwriter for an IPO and those that don't need to raise capital immediately. They want to go public because of the many benefits that being a public company offers such as increased valuation, using public stock as currency to acquire other companies and assets, liquidity, prestige and to reduce the need for expensive venture capital and other financing sources. It also makes it easier to raise capital since once you become public it gives you credibility and a benchmark trading price to raise capital against.
Public companies are typically valued higher than their private counterparts. So, what many sophisticated CEO's and CFO's do is go public without simultaneously raising capital and thus receive a higher valuation and benchmark stock trading price. Then, as a public company, they do a private placement at a deep discount to the market with the provision that the investors hold the stock for 1 year.
Example of How to Use the Power of a Public Company to Raise Capital
As an example, a company goes public without initially raising capital and begins trading on the open market at US $20.00 per share. An individual can go on the internet or into a stock brokerage firm and buy stock at $20.00 per share. Public companies in this situation often sell stock in a private placement at a very substantial discount to the open market price (in this example, perhaps $17.00 per share). The investors agree to hold the stock for a period of time. The issuer can sell the stock themselves or have small broker/dealers assists them. Because investors can buy the stock at a deep discount to the open market price it gives them quite an incentive to invest.
Learn the Truth about Reverse Mergers and Public Shells
Years ago some companies would do a reverse merger with a public shell to go public. When doing a reverse merger with a public shell it can be very costly in many ways and there are several things you must be aware of or the experience will be a disaster.
There are a couple of different kinds of public shell companies. They are very expensive and are usually filled with many liabilities. If you reverse merge into a public shell (which usually has shareholders and shares that are freely tradable in the float) and then when the stock price goes up these shareholders sell the stock and the price decreases rapidly. This can be very detrimental to a company trying to grow through acquisition. This is far more costly than the price paid to do a reverse merger with a public shell. This is important to comprehend. If you do not understand the importance of a small public float your going public experience may be less then ideal.
Non trading public shell companies are a reporting company usually having 1 or 2 shareholders and they have no use other then lining some public shell stock promoters pocket. This kind of public shell is used by stock promoters to sell you something of no value. They don’t tell you can’t get a stock symbol or begin trading it until you hire a securities attorney or other professional costing more money and that you won’t be able to begin trading for at least 3-4 months after merging with the public shell. Public shell promoters don’t tell you that is will take more time to take you public using a shell company than if we simply took your own company public. A public shell company that is not trading simply add an extra step and do not save you anytime whatsoever. In fact they take longer than if you were just to start the process from scratch for your own corporation. You also have to hire someone to get you through the 3-4 months process which is the more difficult and labor intensive procedure that must be guided by competent professional with many years of experience.
Some think erroneously that a reverse merger with a public shell is a way to go public, which it is buy it is a round about way with an extra step, extra time and extra cost that saves you no time and has no useful purpose. A public shell company promoter might tell you a reverse merger with a non trading public shell is faster. This is simply not the case. Trading on the Pink Sheets is typically the fastest way to go public. A company can rather easily progress to the NASD OTC Bulletin Board later. A company can also progress from the Pink Sheets to NASDAQ as they grow.. A company may also choose to start trading on the NASD OTCBB from inception.
Many recent regulatory have made many practices dealing with reverse mergers and public shells fraught difficulties. Investment banks and regulators really don’t like public shells. We recommend to companies thinking of a reverse merger with a public shell to have an attorney who specializes in Securities Law assist you if you are considering getting involved with a public shell. We are not recommending nor suggesting that you do a reverse merger or that you buy a public shell. If you are thinking of a reverse merger with a public shell company you may contact us so that you avoid any grave consequences.. We will discuss with you your options and show you a quicker, less costly way to go public that does not involve doing a reverse merger (public shell merger).
Learn More about Becoming a Public Company
We offer a free report on Going Public so you can learn how to become a public company. We have offices on the East and West Coast of the United States.
We have the unique perspective of being a firm headed by a Securities attorney. An attorney who has worked and been involved in many transactions involving publicly traded companies including private and public offerings as well as a variety of mergers and acquisitions. In fact he advises other attorneys who have limited experience in this very highly specialized field.
We have reports and newsletters that deal with updates and information on the following subjects: taking your company public, private placement, public shell company rule changes, investment banking, investments, shell corporations, corporate finance, how to go public, stock exchanges, venture capital, business finance and also mergers and acquisitions. We will keep you up to date on matters dealing with market makers, securities law, 15c211, private placement memorandums, PIPES Offerings and securities attorneys. We will keep you updated with the latest events so you can learn how to go public properly.
Go Public Comprehensive Program
We are with you every step of the way through the entire process. We can assist you in incorporating your business right through to getting your stock symbol and listing your stock for public trading.
We also offer a free consultation to presidents, senior executive management, mergers and acquisitions consultants and consultants of companies considering going public.
Referrals from CPA's, Business Brokers, Securities Lawyers, Accounting Firms and Financial Investment Advisors are welcomed.
Sophisticated CEO's, CFO's and Financial Professionals realize a public company is a very powerful tool. This is one of the methods they use to raise capital more easily.
Can Any Company Go Public? Yes!
Many people ask the question, what are the qualifications to go public? Any company, including foreign companies, can go public. You don’t have to have been in business for a certain amount of time and there are no revenue or asset requirements for going public. So, virtually any company qualifies for going public. This is for companies wishing to go public on the Over-the-Counter Bulletin Board (OTCBB). NASDAQ does have certain requirements which are listed on their website. We can assist you in "Going Public" on NASDAQ, NASD, OTCBB, AMEX, or NYSE but smaller companies will usually prefer to go public on the OTCBB or the Pink Sheets because of less cost and less regulations.
Pink Sheets (National Quotations Bureau)
Smaller companies may also consider trading on the "Pink Sheets". This is becoming an increasingly popular option for companies. The electronic "Pink Sheets" (National Quotations Bureau) do not require regular reporting with the SEC nor audited financial's. There are also no asset or revenue requirements. Companies such as Rolls Royce, Nestle, and Heineken trade there. Many CEO's are choosing the "Pink Sheets" now because it offers many of the advantages of the OTCBB and NASDAQ without the SEC reporting requirements and audited financial's.
To trade on the Pink Sheets is very fast and inexpensive. We take you public and assist you with investor relations and other services after you receive your stock ticker symbol. We are one of the firms the Pink Sheets recommend to assist companies that want to go public on the Pink Sheets.
Go Public with Confidence
When going public you want the confidence of a firm founded by a Securities Attorney with more than 3 decades of Securities Law experience. We can assist your company in going public on the NASDAQ, the NASD OTCBB or on the Pink Sheets. A publicly traded company is a very valuable and powerful tool and something to strongly consider. Tiber Creek Corporation is the leading provider of going public services. If you would like to learn more about how to go public please go to our contact us page & tell us about your company.
Understanding Pink Sheets Stocks
by: The Report January 30, 2008
The Gold Report
Add to Your WatchlistAbout this author:
Profile & More Articles
Visit author's site
Become a Contributor Submit an Article Font Size: PrintEmail TweetThis
Say "Pink Sheets" and most people think, "Stay away." Why is there a stigma attached to the stocks that trade on the Pink Sheets? Many people don't know much about them except that the SEC doesn't regulate them. Since many attractive Canadian mining companies' shares trade on the Pink Sheets, we thought it would be worthwhile to talk with Kevin Hudak, an investment advisor who specializes in helping his customers buy shares that trade on the Pink Sheets and educating them about the pros and cons. Kevin, with Financial Network Investment Corp. in Albuquerque, NM, specializes in energy, precious metals and uranium, and says he "can trade stock sold on any major exchange in the world."
Some Background on the Pink Sheets
The Pink Sheets — named for the color of paper the quotes were historically printed on prior to the electronic system — are secondary market sales of stocks that are available on the U. S. Over-the-Counter [OTC] market. "Market Makers" — the brokers who commit to buying and selling the securities of OTC issuers —use the Pink Sheets to publish bid and ask prices.
A company named Pink Sheets LLC, formerly known as the National Quotation Bureau, publishes the Pink Sheets in both hard copy and electronic format. Pink Sheets LLC is not registered with the SEC as a stock exchange, nor does the SEC regulate its activities.
We asked Kevin how a Pink Sheet is created. "Pink Sheets are created by market makers who handle individual stocks. These market makers are people who specialize in one or more individual stocks and their purpose is to help the market remain fluid. They will buy and sell out of their own account, depending on what individual investors want or need. That's the way it's supposed to work," he says.
"However," he adds, "this is one of the reasons why you have to be very careful when your broker places a market order - a market order can be anything the market maker wants it to be; whereas a limit order has very specific parameters. I use limit orders 99% of the time just for this reason - I don't want my client exposed to what a market maker thinks the market should be at that point in time. This is one reason why you don't want to be in a hurry buying companies on the Pink Sheets."
The fact that shares traded on Pink Sheets are unregulated makes some investors wary. And many Broker-Dealers steer unsophisticated investors away from them. In fact, under SEC regulations, brokers are not allowed to solicit the sale of the shares if they are under $5; they can only respond if asked about them.
Do Your Homework
We asked Kevin how he deals with the pitfalls of the unregulated aspect of the Pink Sheets. "They are definitely an unregulated secondary market," he responds, "although there is an inherent risk in all the stock markets. However, Pink Sheet securities carry more risk because they do not require the companies to register with the SEC or stay current in their financial statements. This is a case where an investor needs to know the company's management (extremely important), history, and future prospects."
He adds:
However, if you look at just Canadian public exploration and mining companies, there is a level of disclosure in that Canadian Securities Administrators have what is known as the NI 43-101. National Instrument 43-101 is a law that sets conditions under which public exploration and mining companies are required to publish technical reports. The content of the reports and the qualifications of their authors are specified by the Instrument. The purpose of the Instrument is to ensure that securities commissions and investors are informed on technical matters materially affecting the financial status of the listed companies.
The Instrument may be viewed here or here.
How does a company get traded on Pink Sheets? A market maker has to be willing to trade the stock. Says Kevin, "Many companies want to be traded in this secondary market for exposure to U.S. investors. This is beneficial to the company, since they are always looking for new money to expand their business. That's the only place in the U.S. market where they can be traded, owing to their size and/or nationality. The primary market covers larger companies with higher market caps, greater name recognition and stricter regulation. However, some companies don't realize they are on the Pink Sheets and I know of a few Canadian companies that do not want to be traded in the United States." He adds, "Reasons vary as to why this is so. Maybe it's national pride, desire to remain local, distrust of the U.S.? I really don't know why —I've asked and never really got an answer."
Easier than Buying through Canadian Exchange
We asked Kevin what advantages there are for U.S. investors if they buy shares of Canadian companies using the Pink Sheets instead of purchasing shares on the Toronto Stock Exchange [TSX] or the TSX/Venture Exchange.
For a U.S. investor, buying a Canadian company listed in the Pink Sheets means you don't have to open an account with a Canadian broker or find a broker who has Canadian access. Plus, you avoid the cost of currency exchange, both ways.
Pink sheet securities are OTC securities. They are not listed on exchanges, but are quoted in the daily publication issued by Pink Sheet LLC. They are all traded on-line; it's just a question of whether you use a broker or do it yourself. In the case of the Pink Sheets, the more eyes and ears you have, the better off you are because it is an unregulated secondary market. Read your newsletters, attend conferences and remain educated.
How liquid are pink sheet stocks? Kevin says occasionally he will run into one with no volume, but that's rare:
I assume all of us know that liquid means that we can buy and sell the stock in question in a specified period of time. The majority of the stocks traded on the Pink Sheets are traded every day, some are not. This is when a broker can be beneficial to the investor.
Would he say that Pink Sheets are hard to trade?
Saying they are hard to trade can be misleading. They can be time-consuming in reaching your goals using limit trading and watching market trends. The best way to invest in Pink Sheets is to know your market, the companies and the history of the stock market as a whole — the ups and downs that are temporary glitches and the long-term adjustments dictated by macro economic trends.
For more information, Kevin suggests visiting Pink Sheets and the SEC's information page on the Pink Sheets. Kevin can
3m,your guess is as good as mind btw for this month we have trades over 1/2 billion shares so far.You don't think it could be the mm's covering????????????,that would explain alot.glta
approaching 20 million shares today lets pump up the volume... glta
jp,it all sounds good thanks for the info.Have a great day. glta
#21730 More Info...
It was good to hear from you again. Yes, the price of the bike has changed sinced September. We brought out a new price point at the Anti-Aging Show in December in Vegas and it was very well received. It is:
$19,995 which is a far cry from the original price of $44,500. I, as the national sales director am quite excited about this price as it fits so much better with my clients. We can keep the payments around $500 per month on a lease if that's the way you would wish to go.
Yes, the trial actually WILL BE out very soon now. We have had a lot of hurdles to jump and had no idea of all the red tape they would invovle. They have been done for quite some time but these different agencies have driven us crazy. I will inform you the moment I have them in hand. But, we continue to have great results with clients using the bike. One of my clients, Dr. Tony Battillo in Miami, Fl. bought his SECOND BIKE in November. He was running out of time slots for his clients and needed another one. I will be more than happy to give you his number and he's be happy to share his experiences with you.
We sold several bikes at the show and we are currently taking Pre-Production orders with a down payment of $1,000 which will assure you of getting one of the first bikes. We should be in production in the next month as things did go a bit slower than we had hoped. We are looking at a possible turn out time of around April or May. Is your facility a new or existing one?
I look forward to hearing from you again and would love to Pre-Order a bike for you. Have a great day!
Most Sincerely,
Carol Anglin
National Sales Director
Cardio-Cor
be,thanks for your follow up.glta
bd,i agree with you about wayne,btw he is the only game in town with this product as you know,with that said time will tell. glta
Anyone buying today @ .0001,just curious.glta
bd sounds great maybe we can all meet @ vegas.Hoping for the best. glta
another .0002
gail,looks like maybe the mm's are testing the waters.We have been here before.Still hoping for the best.glta
jp,just curious we all see where the stock is now at the lowest level,and you appear with info trying to figure if you are a good guy or not. .BTW if you don't mind could you tell us what your position is in how many shares you own of cirt.I understand if you don't want to disclose that info.Have a great day. glta
Surf,i notice a couple days back the mm's block info on level 2 dated back a couple of months ago and further.Still hoping for the best. glta,we were @ .0001 x .0002,.0001 since oct. 2008 give or take according to charts. glta Could have accumulated alot of .0001's etc.
Will do,glta
Surf,i agree with you to certain point but the volume picked up at the beginning of this month.Unless that majority of buying came from HQ'S.I have been emailing wayne back in dec. to buyback @ least 500 million shares.Trying to help out.glta
surf,i believe mm's may also be covering,also.Hoping for the best.glta
sent emails couple of days ago no reply as yet.glta
Approaching 60 million shares today????????????????????,glta
3M,may be partially what you just posted plus i believe mm's may also be covering,also.Hoping for the best.glta
48.5 million lets keep rocking ????????????? glta
44.5 million so far today are we going to hit a 100 million today? any takers .glta
41 million,LETS PUMP UP THE VOLUME. GLTA
jp ?,really appreciate the insight just give us the good stuff and know fluff.I hope your one of the good guys.btw WELCOME ABOARD,any idea how soon a pr will hit.I am expecting anyday now.glta
jp,i see your a new guy on the block as far as posting goes.But i really believe you have been around for quite awhile.Wishful guessing prove me wrong.glta
Transfer agent:
Have you tried recently, Justblank2000@yahoo.com ... glta
Surf,are you out lurking about. glta
jjtm,With regards to the first bike that Bob ordered from CIRT, it was on the truck and then unfortunately, he had to cancel the order and send the bike back due to the Canadian dollar devaluation. He did say he put down a deposit and that money is still with CIRT and will remain there. Carol states that Bob feels really bad about this, but she reiterated the same thing that Bob told me, in the fact that he feels terrible about having to delay the first order. glta
gail thanks anyway,have a great day. glta
ms40,i hope they will be reporting soon.According to there pr's it should be good.Still waiting on mia info/contract see how that plays out.glta
gail,i feel the same way i hope its accurate or legit.The price is around 20k it says.Could you call carol and verify that at least,if you have a chance i already emailed her and wayne but know reply as of yet.glta
Thanks for info that explains it.
Surf,i wish we could get a update from MKA.glta
Surf,you can buy millions for very little money at this level already have mine.GLTA